Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 17/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | FGR | P09769 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21187714 | 0.88 | RET (0.79) | RETKDRCYP1A2HCKFGR | |
| SCHEMBL21178779 | 0.85 | RET (0.73) | RETKDRCYP1A2HCKFGR | |
| SCHEMBL31639920 | 0.85 | RET (0.73) | RETKDRCYP1A2HCKFGR | |
| SCHEMBL21187519 | 0.84 | RET (1.00) | RETKDRCYP1A2HCKFGR | |
| SCHEMBL31640028 | 0.83 | RET (0.71) | RETKDRTEKLCKSRC | |
| SCHEMBL21178867 | 0.83 | RET (1.00) | RETKDRCYP1A2HCKFGR | |
| SCHEMBL21178848 | 0.81 | RET (1.00) | RETKDRTEKLCKSRC | |
| SCHEMBL22605132 | 0.81 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL28481350 | 0.81 | RET (0.67) | RET | |
| SCHEMBL21179092 | 0.80 | RET (0.69) | RETKDRCYP1A2HCKFGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-111971286-B | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3740491-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| CN-111971286-A | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20200339589-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200339589-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-10-29 | — | — | US | disclosed |
| WO-2019143977-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143977-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339589-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FGFR3 | RET 1/4885KDR 181/4885CYP1A2 3782/4885 |
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | RET, ROR1, FGFR3 | RET 1/4885KDR 181/4885CYP1A2 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.